Aptevo Therapeutics Ownership
| APVO Stock | USD 2.57 0.10 4.05% |
Shares in Circulation | First Issued 2015-03-31 | Previous Quarter 285 K | Current Value 285 K | Avarage Shares Outstanding 217.9 K | Quarterly Volatility 784 K |
Aptevo |
Aptevo Stock Ownership Analysis
The company has price-to-book (P/B) ratio of 0.76. Some equities with similar Price to Book (P/B) outperform the market in the long run. Aptevo Therapeutics recorded a loss per share of 87.38. The entity last dividend was issued on the 27th of March 2020. The firm had 1:37 split on the 4th of December 2024. Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington. Aptevo Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 54 people. For more info on Aptevo Therapeutics please contact Marvin White at 206 838 0500 or go to https://aptevotherapeutics.com.Besides selling stocks to institutional investors, Aptevo Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Aptevo Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Aptevo Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Aptevo Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Aptevo Therapeutics Insider Trades History
Less than 1% of Aptevo Therapeutics are currently held by insiders. Unlike Aptevo Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Aptevo Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Aptevo Therapeutics' insider trades
Aptevo Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Aptevo Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Aptevo Therapeutics backward and forwards among themselves. Aptevo Therapeutics' institutional investor refers to the entity that pools money to purchase Aptevo Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of America Corp | 2024-12-31 | 4.0 | Truvestments Capital Llc | 2024-09-30 | 2.0 | Jane Street Group Llc | 2024-12-31 | 0.0 | Wells Fargo & Co | 2024-12-31 | 0.0 | Northern Trust Investments N A | 2024-12-31 | 0.0 | Citadel Advisors Llc | 2024-12-31 | 0.0 | Two Sigma Investments Llc | 2024-12-31 | 0.0 | Sabby Management Llc | 2024-09-30 | 0.0 | Hudson Bay Capital Management Lp | 2024-12-31 | 0.0 | Virtu Financial Llc | 2024-12-31 | 21.6 K | Hrt Financial Llc | 2024-12-31 | 12.3 K |
Aptevo Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aptevo Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aptevo Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aptevo Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Aptevo Therapeutics Outstanding Bonds
Aptevo Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Aptevo Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Aptevo bonds can be classified according to their maturity, which is the date when Aptevo Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US03835VAH96 Corp BondUS03835VAH96 | View | |
| Aptiv 435 percent Corp BondUS03835VAG14 | View | |
| APTIV PLC 44 Corp BondUS03835VAF31 | View | |
| APTV 31 01 DEC 51 Corp BondUS03835VAJ52 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| ATR 36 15 MAR 32 Corp BondUS038336AA11 | View | |
| US03836WAC73 Corp BondUS03836WAC73 | View |
Aptevo Therapeutics Corporate Filings
8K | 20th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 4th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
S1 | 3rd of March 2025 Report filed by companies planning on going public to register their securities with the U.S. Securities and Exchange Commission (SEC) | ViewVerify |
| 10th of February 2025 Other Reports | ViewVerify |
Pair Trading with Aptevo Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aptevo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aptevo Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Aptevo Stock
Moving against Aptevo Stock
| 0.88 | CMRX | Chimerix | PairCorr |
| 0.86 | CPIX | Cumberland Pharmaceuticals Downward Rally | PairCorr |
| 0.74 | FNA | Paragon 28 | PairCorr |
The ability to find closely correlated positions to Aptevo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aptevo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aptevo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aptevo Therapeutics to buy it.
The correlation of Aptevo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aptevo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aptevo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aptevo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptevo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptevo Therapeutics. If investors know Aptevo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptevo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Aptevo Therapeutics is measured differently than its book value, which is the value of Aptevo that is recorded on the company's balance sheet. Investors also form their own opinion of Aptevo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aptevo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptevo Therapeutics' market value can be influenced by many factors that don't directly affect Aptevo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aptevo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptevo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptevo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.